Alvotech S.A.: Alvotech Reports Financial Results for the First Nine Months of 2024
Total Revenues in the first nine months of 2024 increased by $300 million compared to same period in 2023, to $339 million, with Q3 revenues contributing $103 millionProduct revenues in the first nine ...
ALK Licenses Rights To Neffy®, The First Approved Adrenaline Nasal Spray For Emergency Treatment Of Allergic Reactions (Anaphylaxis)
ALK (ALKB:DC / OMX: ALK B) today announced that it has entered into a strategic license agreement with US-based ARS Pharmaceuticals, <a target= ...